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(FKRP) gene cause limb-girdle muscular dystrophy type
2I (LGMD2I) and other forms of congenital muscular dystro-
phy-dystroglycanopathy that are associated with glycosylation
defects in the a-dystroglycan (a-DG) protein. Systemic admin-
istration of a single dose of recombinant adeno-associated virus
serotype 9 (AAV9) vector expressing human FKRP to a mouse
model of LGMD2I at various stages of disease progression was
evaluated. The results demonstrate rescue of functional glyco-
sylation of a-DG and muscle function, along with improve-
ments in muscle structure at all disease stages versus age-
matched untreated cohorts. Nevertheless, mice treated in the
latter stages of disease progression revealed a decrease in bene-
ficial effects of the treatment. The results provide a proof of
concept for future clinical trials in patients with FKRP-related
muscular dystrophy and demonstrate that AAV-mediated gene
therapy can potentially benefit patients at all stages of disease
progression, but earlier intervention would be highly preferred.Received 30 December 2016; accepted 20 February 2017;
http://dx.doi.org/10.1016/j.omtm.2017.02.002.
Correspondence: Charles Harvey Vannoy, McColl-Lockwood Laboratory for
Muscular Dystrophy Research, Cannon Research Center, Carolinas Medical Cen-
ter, Carolinas Healthcare System, Charlotte, NC 28203, USA.
E-mail: charles.vannoy@carolinashealthcare.org
Correspondence: Qi Long Lu, McColl-Lockwood Laboratory for Muscular Dys-
trophy Research, Cannon Research Center, Carolinas Medical Center, Carolinas
Healthcare System, Charlotte, NC 28203, USA.
E-mail: qi.lu@carolinashealthcare.orgINTRODUCTION
Dystroglycanopathies are a subgroup of muscular dystrophy that
result from aberrant glycosylation of a-dystroglycan (a-DG) and
are characterized pathologically by muscle fiber degeneration and
clinically by progressive muscle weakness.1 These disorders are
caused by mutations in a multitude of genes, including the gene en-
coding Fukutin-related protein (FKRP; OMIM 606596). The FKRP
gene, along with fukutin, is part of a family of genes that possess
the putative catalytic DXD motif—a conserved motif found in
many families of glycosyltransferases—and is predicted to function
as a ribitol 5-phosphate transferase, which is fundamentally required
for the post-translational modification of a-DG.2–5 In normal tissues,
the mucin-like domain of a-DG is modified with numerous oligosac-
charides that are essential for function—anchor the structural frame-
work inside each cell (cytoskeleton) to the lattice of extracellular
matrix proteins.6–8 Missense mutations in the FKRP gene lead to
FKRP protein deficiencies that impair the glycosylation pathway of
a-DG.9,10 As a consequence of reduced FKRP protein activity,
a-DG is hypoglycosylated and has a reduced binding capacity to
the extracellular matrix proteins, effectively weakening the bridgeMolecular Therapy: Method
This is an open access article undebetween the dystrophin-glycoprotein complex and the extracellular
matrix and disrupting the skeletal muscle basal lamina.11
Mutations in the FKRP gene exhibit a wide spectrum of clinical
severity, ranging from severe congenital muscular dystrophies to
limb-girdle muscular dystrophy type 2I (LGMD2I).9,10,12 LGMD2I
can present as mild or severe depending on the age of onset. Early
childhood onset of LGMD2I usually indicates a severe clinical course
with affected individuals becoming non-ambulatory as early as their
teens. The late- or adult-onset form of LGMD2I is a slowly progres-
sive, milder form of the disorder. Respiratory and cardiac involve-
ment is prominent in all disease severities.13 The variable phenotypic
severity has been partly attributed to the differences in location of
point mutations within the coding sequence, affecting protein trans-
portation and its glycosyltransferase activity differentially.14–16
Therefore, it is likely that any type of therapeutic intervention could
potentially have different efficacies for individuals at different stages
of disease progression.
Currently, recombinant adeno-associated virus (AAV) gene therapy
is one of the most promising strategies for replacing a gene with
loss-of-function mutations. AAV is a small (25 nm in diameter) hu-
man parvovirus that packages a linear single-stranded DNA genome
and is replication defective. The lack of pathogenicity of the virus and
its ability to persist stably in transduced cells, especially in post-pro-
liferative muscle tissues, make it a desirable and effective delivery
vehicle for gene therapy applications to muscular dystrophies.17,18
As a result, AAV gene therapy has been tested in various animal
models of many limb-girdle muscular dystrophies,19–24 along with
ongoing/completed clinical trials for dysferlinopathy (ClinicalTrials.s & Clinical Development Vol. 5 June 2017 ª 2017 The Author(s). 31
r the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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www.moleculartherapy.orggov identifier NCT02710500), LGMD2C (g-sarcoglycan)
(ClinicalTrials.gov identifier NCT01344798), and LGMD2D (a-sar-
coglycan) (ClinicalTrials.gov identifier NCT00494195).
In this study, an AAV serotype 9 vector containing a full-length hu-
man FKRP gene (AAV9-FKRP) under control of a muscle creatine
kinase-based promoter was administered by a single intravenous
tail-vein injection at a dose of 2.5 1013 vector genomes per kilogram
(vg/kg) at onset or later stages of disease progression in our dystro-
phic mouse model containing a missense mutation in the FKRP
gene. Our objective is to systematically evaluate the therapeutic po-
tential of AAV-mediated FKRP gene delivery and assess the efficacy
of the gene replacement therapy for individuals with LGMD2I exhib-
iting various degrees of disease pathology before a viable treatment
option is available.
RESULTS
Systemic FKRPDeliveryRestores Functionala-DG inDystrophic
Mice
For these experiments, we used a mouse model containing a homozy-
gous missense mutation (c.1343C > T, p.Pro448Leu) in the FKRP
gene (FKRPP448L mutant), as previously described.25,26 Onset of the
dystrophic attributes can be observed as early as 3 weeks, with pro-
gressive pathological changes as the mouse ages. Accordingly, we
formulated four age groups of FKRPP448L mutant mice (5, 13, 26,
and 39 weeks of age) representing disease progression from an early
stage, when muscle degeneration has just become clearly identifiable,
to a late stage characterized by severe dystrophy and fibrosis in skel-
etal muscles and noticeable defects in cardiac muscle function. To
correct for the FKRP deficiency, we utilized a skeletal/cardiac
muscle-tropic AAV serotype 9 vector expressing a full-length human
FKRP coding sequence under control of a muscle-specific creatine
kinase-based (CK7) promoter (AAV9-CK7-HuFKRP, abbreviated
as AAV9-FKRP) (Figure S1). A single tail-vein injection of
AAV9-FKRP at a dose of 2.5  1013 vg/kg was administered to all
age groups. Mice were monitored and functionally assessed for a
13-week period and then were subsequently euthanized for analysis,
giving rise to cohorts T18, T26, T39, and T52, respectively (Fig-
ure 1A). Age-matched untreated FKRPP448L mutant mice were used
as negative controls. All mice remained healthy in appearance, activ-
ity, and body weight over the 13-week observation period.
Analysis of glycosylation on a-DG by immunohistochemistry at
euthanasia demonstrates that intravenous delivery of AAV9-FKRP
reconstituted functional glycosylation of a-DG in skeletal musclesFigure 1. Study Design and Rescue of a-DG Glycosylation in Dystrophic Mice
(A) Experimental design of FKRPP448L mutant mice injected with AAV9-FKRP at 5 (T18, n
treatment study. (B) Immunofluorescence staining of glycosylated a-DG in tibialis anterio
blot analysis of glycosylated a-DG expression in tibialis anterior, diaphragm, and heart
Glycosylated a-DG was detected with the IIH6C4 antibody at a dilution of 1:200 and
antibodywas used as the protein loading control. (D)Western blot analysis of exogenous
an FKRP (C-terminal) antibody at a dilution of 1:400. Anti-GAPDH antibody was used as
was analyzed by quantitative real-time PCR methods. All levels are relative to those in u
Molthroughout the body, including the heart (Figure 1B). Age-dependent
variation in levels of functional glycosylation of a-DG was visualized
by immunohistochemistry with a monoclonal anti-a-DG antibody
(IIH6C4) specific to glycosylated epitopes on a-DG,27 also known
as functional a-DG. The IIH6C4 signals were localized to the sarco-
lemma and relatively homogeneous in a large portion of muscle fibers
and were generally higher in the diaphragm and heart compared to
the skeletal muscles, which is likely due to the higher tropism of
AAV9 to the cardiac muscle. Positive signals were relatively stronger
in the muscles of the early-stage treatment cohorts in comparison to
the late-stage cohorts, especially in the skeletal muscles. In stark
contrast, a positive immunofluorescence signal for functionally glyco-
sylated a-DG was undetectable in all muscles of the age-matched un-
treated cohorts, except for a few revertant fibers in the tibialis anterior
muscles. Western blot analysis confirmed that the AAV-treated mus-
cle produced normal glycosylated forms of a-DG (150–250 kDa; car-
bohydrate composition differs depending on tissue type) similar to
that detected in the same muscle type of wild-type tissue (Figure 1C).
Similar to the immunofluorescence staining, the levels of functional
glycosylation were evidently different in all tissues between the
early- and late-stage treatment cohorts, with the highest levels in
the T18 cohort and lowest levels in the T52 cohort. Only 12%, 34%,
and 53% of normal levels of functionally glycosylated a-DG were de-
tected in the tibialis anterior, diaphragm, and heart muscles of the
oldest T52 age cohort, respectively, whereas approximately 87%,
88%, and 70% of normal levels were detected in the corresponding
three muscles from the youngest T18 cohort. Interestingly, an age-
related decrease in levels of functionally glycosylated a-DG was also
muscle-type dependent, predominantly in the tibialis anterior muscle.
As expected, there was little or no immunoreactivity detectable in the
age-matched untreated FKRPP448L mutant samples. IIH6C4 expres-
sion in the tibialis anterior was representative of all skeletal muscles
tested (quadriceps, gastrocnemius, bicep, and triceps; data not
shown).
Western blot (Figure 1D) and quantitative real-time PCR analysis
(Figure 1E) demonstrated similar levels of FKRP transgene expression
in the AAV-treated cohorts. Expression of vector-driven FKRP pro-
tein was analyzed on whole-muscle lysates by western blotting with
an antibody raised against a peptide mapping near the C terminus
of FKRP (human origin). FKRP protein was clearly detected in the ti-
bialis anterior muscle of all AAV-treated cohorts, with a distinct
signal band at approximately 110 kDa that corresponds to a dimeric
FKRP. The intensity of the FKRP signal was similar for all AAV-
treated cohorts, whereas it was undetectable in all age-matched= 4), 13 (T26, n = 4), 26 (T39, n = 4), and 39 weeks of age (T52, n = 4) in a 13-week
r, diaphragm, and heart tissue from indicated mice. Scale bars, 200 mm. (C) Western
tissue from FKRPP448L mutant mice injected with AAV9-FKRP (+) or untreated ().
1:1,000 for immunofluorescence staining and western blot, respectively. Anti-actin
FKRP protein in tibialis anterior tissues from indicatedmice. FKRPwas detected with
the protein loading control. (E) FKRP transgene expression in tibialis anterior tissues
ntreated FKRPP448L mutant mice cohorts and have been normalized using GAPDH.
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Figure 2. FKRP Gene Therapy Improves the Internal Structure and Hyper-/Hypotrophy of Skeletal and Cardiac Muscle Fibers
(A) Cross-sections from tibialis anterior, diaphragm, and heart tissue of AAV-treated and FKRPP448L mutant mice stained with H&E. Scale bars, 100 mm. (B) Quantification of
centrally nucleated fibers in AAV-treated and untreated FKRPP448L mutant tibialis anterior muscles (n = 4). ***p% 0.001 (Student’s t test, each condition versus age-matched
FKRPP448L mutant mice). (C) The equivalent radius of individual myofibers in tibialis anterior muscles from FKRPP448L mutant mice injected with AAV9-FKRP (+) or untreated
() for each cohort (n = 4).
Molecular Therapy: Methods & Clinical Developmentuntreated FKRPP448L mutant samples. We also validated the
expression level of the FKRP transgene by quantitative real-time
PCR analysis in all AAV-treated and age-matched untreated
FKRPP448L mutant cohorts. These results show that a single injection
of AAV9-FKRP is efficacious in rescuing functional glycosylation of
a-DG in FKRPP448L mutant mice at all stages of disease pathology.
AAV9-FKRP Gene Therapy Improves Muscle Pathology
Similar to the clinical severity observed in patients with LGMD2I,
FKRPP448L mutant mice exhibit a mild-to-moderate phenotype of
muscular dystrophy represented as myofiber regeneration/degenera-34 Molecular Therapy: Methods & Clinical Development Vol. 5 June 2017tion, significant fiber size variability, mononuclear cell infiltration,
and pronounced fibrosis in the later stages of disease progression. Ex-
amination of the muscle morphology by H&E staining indicates that
degeneration/regeneration in the limb skeletal muscles of the un-
treated FKRPP448L mutant begins to plateau around 26 weeks of
age, as demonstrated by the presence of large areas of necrotic fibers
and a considerable number of centrally nucleated fibers (Figure 2A).
An increase in fibrosis becomes clearly recognizable in the diaphragm
and functional defects in skeletal and cardiorespiratory systems
become detectable from the age of 26 weeks onward. Conversely, sys-
temic FKRP gene delivery ameliorated pathological phenotypes of the
Figure 3. Gene Therapy with AAV9-FKRP Slows the Progression of Fibrosis in the Diaphragm
(A) Masson’s trichrome staining of diaphragm tissue of AAV-treated and FKRPP448L mutant mice in each cohort. Scale bar, 200 mm. (B) Quantification of the fibrotic area of
the diaphragm in AAV-treated and FKRPP448L mutant mice for each cohort (n = 4). **p % 0.01; ***p % 0.001 (Student’s t test, each condition versus age-matched
FKRPP448L mutant mice).
www.moleculartherapy.orgdystrophic skeletal muscles of all mice from both early- and late-
treated cohorts, which included a normalization of fiber size distribu-
tion, a reduction in centralized nuclei, and less pronounced fibrosis.
Quantitative analysis of the tibialis anterior muscles from each cohort
of untreated FKRPP448L mutant mice showed that the number of cen-
trally nucleated fibers increased from younger to older cohorts, with
30.8% ± 3.1%, 42.2% ± 5.4%, 57.0% ± 4.6%, and 54.9% ± 2.1%, from
T18 to T52, respectively, reaching a plateau around 39 weeks of age
(Figure 2B). In contrast, the T18 cohort from the AAV-treated
mice contained a significantly smaller percentage (11.0% ± 1.2%,
p % 0.001) of centrally nucleated fibers. This percentage also
decreased in the T26 (36.0% ± 2.6%, p = 0.3399), T39 (46.6% ±
1.5%, p = 0.0730), and T52 (48.5% ± 1.8%, p = 0.0633) cohorts
from the AAV-treated mice, but it lacked significance compared to
the age-matched untreated controls. The similar percentage of cen-
trally nucleated fibers in the two older (T39 and T52) cohorts is
consistent with the notion that muscle degeneration and regeneration
reaches a plateau around 26 weeks of age in FKRPP448L mutant mice
and that the time required for peripheralization of nuclei could take
several months or longer to complete. Quantitative analysis of the col-
lective myofiber radius revealed a decreased proportion of fibers with
large and small diameters representing hypertrophy and regenerating
fibers, respectively, in all cohorts of the AAV-treated muscles when
compared to untreated FKRPP448L mice (Figure 2C). The population
of large fibers (>40 mm) was very small in the T18 cohort, and the dif-
ference between treated and untreated FKRPP448L mutant mice was
not clear. Together, these results suggest a normalization of fiber
size distribution, representing a clear deceleration or halting of pro-
longed cycles of regeneration/degeneration.
Another histological hallmark of the FKRPP448L mutant mouse is pro-
nounced and progressive fibrosis in the diaphragm as the mouse ages.
To evaluate fibrotic changes after treatment, Masson’s trichrome
staining was performed on tissue sections of the diaphragm from
each cohort (Figure 3A). The results show a significant reduction in
the amount of collagen present within AAV-treated cohortsMolcompared with the untreated cohorts. Quantitative data confirmed
that deposition of connective tissues follows a linear increase with
age in both AAV-treated and untreated FKRPP448L mutant mice (Fig-
ure 3B). More importantly, areas of connective tissue were signifi-
cantly more prominent in untreated FKRPP448L mutant mice
compared to AAV-treated mice within each age cohort (T52:
56.2% ± 2.4% versus 45.7% ± 0.7%, p = 0.0060; T39: 44.2% ± 1.7%
versus 35.5% ± 0.9%, p = 0.0051; T26: 32.0% ± 0.7% versus
20.5% ± 1.3%, p = 0.0002; and T18: 22.8% ± 1.3% versus 9.5% ±
0.9%, p = 0.0002). Quantitative comparisons additionally reveal
that AAV-mediated delivery of FKRP to FKRPP448L mutant mice re-
duces the level of fibrosis of each treatment cohort to a similar level of
a younger untreated cohort corresponding to the treatment interven-
tion time point (Table S1). Collectively, these results demonstrate that
timely administration of an intervention that restores functionally
glycosylated a-DG can slow or halt the development of fibrosis in
the diaphragm before irreversible damage can occur.
Gene Therapy with AAV9-FKRP Improves Muscle Function
To assess the effect of rescuing functionally glycosylated a-DG on
physical function, we conducted treadmill exhaustion tests 11 weeks
post-injection. Initially, the mice were allowed to undergo an acclima-
tion period, after which the test was started and mice were run to the
point of exhaustion. The untreated FKRPP448L mutant mice showed a
reduced tolerance to exercise compared with AAV-treated mice (Fig-
ures 4A–4C). On average, mice from each AAV-treated cohort ran
approximately 20%–28% longer at higher speeds than age-matched
untreated FKRPP448L mutant mice. Also, AAV-treated mice were
able to run longer distances than age-matched untreated FKRPP448L
mutant mice, although a gradual decline was observed for both as
age increased (untreated FKRPP448L mutant versus AAV-treated
mice, respectively: T18: 140.3 ± 9.6 versus 203.3 ± 38.4 m, p =
0.1623; T26: 96.3 ± 9.5 versus 152.5 ± 37.5 m, p = 0.1962; T39:
81.8 ± 5.5 versus 113.5 ± 15.9 m, p = 0.1075; and T52: 71.0 ± 7.2
versus 122.3 ± 22.0 m, p = 0.0690). Together, these data indicate
that muscle impairment can be ameliorated at all stages of disease
progression.ecular Therapy: Methods & Clinical Development Vol. 5 June 2017 35
Figure 4. Improvement of Muscle Performance and Body Weight
(A–C) Treadmill exhaustion test assessing the running time until exhaustion (A), distance covered (B), and maximum running speed (C) of AAV-treated and FKRPP448L mutant
mice in each cohort. (D) Percent change in body weight observed from initial treatment to euthanasia. *p % 0.05 (Student’s t test, each condition versus age-matched
FKRPP448L mutant mice).
Molecular Therapy: Methods & Clinical DevelopmentThe assessment of body weight (measured every 6–7 weeks) was re-
ported as a percent change relative to baseline and revealed that all
study groups gained body mass over the 13-week observation period,
except for untreated FKRPP448L mutant mice in the T52 cohort (Fig-
ures 4D and S2). No significant difference was observed between
the AAV-treated and untreated FKRPP448L mutant mice in the T18,
T26, or T39 cohorts.
Effect of AAV9-FKRP Treatment on Respiratory and Cardiac
Parameters
To evaluate respiratory function, unrestrained and conscious AAV-
treated and untreated FKRPP448L mutant mice were monitored by
whole-body plethysmography. This non-invasive technique provides
a comprehensive pulmonary analysis by measuring sensitive respira-
tory parameters that include breathing frequency (F; the number of
breaths per minute), tidal volume (TV; amount of air inhaled and
exhaled normally at rest), minute volume (MV; amount of air inhaled
and exhaled per minute), peak inspiratory flow (PIF; maximal flow
rate achieved during the inspiratory cycle), and peak expiratory
flow (PEF; maximal flow rate achieved during the maximally forced
expiration initiated at full inspiration) (Table 1). Analysis of the re-
sults indicates an improvement trend in a majority of the respiratory
parameters of the early-stage AAV-treated cohorts (T18 and T26)
when compared to age-matched untreated FKRPP448L mutant mice.
However, no statistical significance was reached with the small size
of the cohorts. Consistent with more progressive fibrosis in the dia-
phragm as observed from H&E and Masson’s trichrome staining,36 Molecular Therapy: Methods & Clinical Development Vol. 5 June 2017minimal or no improvement at all is observed with the late-stage
AAV-treated cohorts (T39 and T52). Assessment of cardiac
morphology and function was conducted via echocardiography and
summarized (Table S2). The results indicate that there was no sig-
nificant difference in cardiac morphology or function between the
AAV-treated and untreated FKRPP448L mutant mice cohorts at
each time point.
DISCUSSION
Great advancements have been made in transforming gene replace-
ment therapy into an efficient, sustainable method for treating dystro-
phic disorders. However, many questions remain to be answered
before the therapeutic approach can be effective in a clinical study
focused on a majority of patients with muscular dystrophy. Pre-clin-
ical studies related to muscular dystrophy have proven that AAV-
mediated delivery can result in transgenic expression at therapeutic
levels in body-wide skeletal muscles and organs of interest. Recently,
our research group and collaborators reported that AAV-mediated
delivery of FKRP was able to effectively express sufficient levels of
FKRP protein, triggering the restoration of functional glycosylation
of a-DG in mouse models of LGMD2I containing point mutations
of proline to leucine at position 448 (FKRPP448L) and leucine to
isoleucine at position 276 (FKRPL276I).22,23 Administration at an early
stage of the disease ameliorated disease progression, with significant
improvement in dystrophic pathology, serum creatine kinase levels,
and muscle function void of any deleterious evidence. The results
showed that transgenic FKRP expression, levels of functionally
Table 1. Assessment of Respiratory Function
Post-injection Time
Pointa
T18 T26 T39 T52
AAV Treated FKRPP448L Mutant AAV Treated FKRPP448L Mutant AAV Treated FKRPP448L Mutant AAV Treated FKRPP448L Mutant
F (Breaths/min)
1 week 248.56 ± 5.86 253.70 ± 3.36 258.55 ± 5.44 260.36 ± 6.12 279.01 ± 13.32 271.63 ± 5.22 276.15 ± 5.93 270.64 ± 8.90
13 weeks 273.73 ± 6.08 275.58 ± 8.15 244.77 ± 1.15 268.89 ± 9.32 284.20 ± 18.54 289.85 ± 10.91 262.74 ± 12.80 276.03 ± 22.34
Percent change 10.1 8.6 5.3 3.3 1.9 6.7 4.9 2.0
TV (mL)
1 week 0.16 ± 0.01 0.16 ± 0.01 0.17 ± 0.01 0.18 ± 0.00 0.25 ± 0.02 0.24 ± 0.02 0.22 ± 0.02 0.21 ± 0.02
13 weeks 0.26 ± 0.02 0.23 ± 0.01 0.27 ± 0.03 0.25 ± 0.01 0.26 ± 0.03 0.24 ± 0.01 0.21 ± 0.01 0.21 ± 0.02
Percent change 60.1 45.6 59.1 34.1 1.7 0.2 5.4 2.0
MV (mL)
1 week 40.29 ± 2.30 39.78 ± 1.67 43.13 ± 1.80 47.98 ± 1.66 71.15 ± 8.53 64.26 ± 6.34 61.92 ± 5.74 57.05 ± 6.33
13 weeks 71.26 ± 6.96 62.73 ± 5.06 64.76 ± 6.55 67.01 ± 3.29 74.10 ± 10.75 68.23 ± 5.39 55.52 ± 4.86 60.45 ± 10.00
Percent change 76.9 57.7 50.1 39.7 4.1 6.2 10.3 5.9
PIF (mL/s)
1 week 5.98 ± 0.19 5.95 ± 0.23 6.34 ± 0.18 6.78 ± 0.35 6.87 ± 0.34 6.75 ± 0.45 5.78 ± 0.45 5.68 ± 0.51
13 weeks 6.73 ± 0.53 6.32 ± 0.25 7.08 ± 0.61 6.38 ± 0.37 6.40 ± 0.43 5.57 ± 0.18 5.10 ± 0.15 5.00 ± 0.35
Percent change 12.7 6.4 11.7 6.0 6.8 17.5 11.8 12.0
PEF (mL/s)
1 week 3.38 ± 0.18 3.92 ± 0.14 3.94 ± 0.23 4.13 ± 0.25 4.01 ± 0.32 4.08 ± 0.31 3.57 ± 0.23 3.42 ± 0.18
13 weeks 4.12 ± 0.32 4.07 ± 0.19 4.05 ± 0.30 3.81 ± 0.20 4.08 ± 0.37 4.00 ± 0.13 3.35 ± 0.17 3.61 ± 0.21
Percent change 21.9 3.9 2.6 7.9 1.6 2.1 6.2 5.5
Respiratory function parameters in AAV-treated and FKRPP448L mutant mice for T18, T26, T39, and T52 cohorts at post-injection time point intervals of 1 and 13 weeks. F, breathing
frequency; MV, minute volume; PEF, peak expiratory flow; PIF, peak inspiratory flow; TV, tidal volume.
aPercent change from 1 to 13 weeks.
www.moleculartherapy.orgglycosylated a-DG, and other therapeutic effects persisted long after
treatment. However, disease progression of muscular dystrophy is the
result of muscle wasting and accumulation of fibrotic tissue, both of
which are likely to have a profound effect on the efficacy of gene
therapy. Consequently, knowing the degree of efficacy that can be
achieved in individuals with different severities or at different stages
of disease progression is critical.
To our knowledge, we are the first to demonstrate the phenotypic
correction of FKRP-related muscular dystrophies at multiple stages
of disease progression in a mouse model by a single intravenous
administration of an AAV vector. The results of this study address
the important issue as to whether gene replacement will have similar
efficacies at different stages of disease progression. This is especially
important because FKRP-related muscular dystrophies exhibit a
wide spectrum of clinical severity, variability in age at onset, and vary-
ing degrees of myogenic atrophy. These variables significantly
complicate the clinical study process, including population selection,
dose determination, and comprehensive evaluation of the results.
However, these challenges can be overcome by understanding the ef-
fect of the underlying variables to the therapy in animal models rele-
vant to clinical manifestations. We propose that several aspects of the
disease can be conjectured to affect the efficiency of transgene expres-Molsion and efficacy of the therapy. Specifically, pathological changes
with aging and an increasing amount of fibrosis with disease progres-
sion are two important factors that can determine the efficiency of
transgene expression and its functional impact on diseased muscles.
Our FKRPP448L mutant mouse model serves this purpose well by pre-
senting dystrophic phenotypes that closely resemble those demon-
strated in patients with LGMD2I. This model exhibits severely
reduced expression of functionally glycosylated a-DG in all skeletal
and cardiac muscles, along with progressive degeneration as the
mouse ages, which is associated with a gradual loss of muscle mass
and an increase in fibrosis, especially in the diaphragm.
Our results indicate that administration of AAV9-FKRP at a dose of
2.5  1013 vg/kg has the greatest therapeutic effect in the youngest
T18 cohort. This includes the highest levels of restoration of func-
tional glycosylation of a-DG, maximum improvement in both skel-
etal and respiratory functions, and prevention of dystrophic pathol-
ogy. Treatment at later stages of disease progression also improves
pathology and functions, but at reduced rates. More importantly,
the therapeutic effect could only reach a level similar to the point at
which the treatment was initiated. For example, AAV-treated mice
in the T39 cohort (treated at 26 weeks of age) showed a reduced per-
centage of centrally nucleated fibers as well as reduced areas of fibroticecular Therapy: Methods & Clinical Development Vol. 5 June 2017 37
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treated FKRPP448L mutant T26 cohort. This could be due, in part,
to the fact that even though AAV9 demonstrates early expression
(within 7 days post-injection), maximum vector expression may
not occur until 100 days post-injection.28 A similar trend is evidenced
in the functional indices assessed by the treadmill exhaustion test.
Therefore, the results support the notion that it may be difficult for
an AAV gene therapy to reverse existing pathological changes such
as fibrosis and fragmented fibers that can hinder the function of
diseased muscles. It remains to be investigated as to whether a higher
dose and prolonged period of treatment could further improve func-
tional outcomes of skeletal, respiratory, and cardiac muscles, reaching
statistical significance in all cohorts.
In general, the correction of dystrophic muscle pathology is highly
dependent on the restoration of functional glycosylation of a-DG.
We observed that the rescue of functional glycosylation of a-DG
was variable between tissues in the treated mice and the amount
was highly dependent on the age at which the mouse was treated.
The reason behind the lower levels of functionally glycosylated
a-DG in muscles, especially skeletal muscles, of the late-stage treated
cohorts is not clearly understood. One possible explanation is that
there is a lower level of infectivity of AAV in the muscles of older
mice, which have experienced progressive accumulation of the extra-
cellular matrix, thereby reducing the accessibility of the virus to
dystrophic fibers. Another possible explanation is that the persistent
degeneration is expected to lead to a loss of viral vectors, especially
before transgene expression is able to achieve its protective effect.
This theory is consistent in tissues where degeneration and fibrosis
are minimal and progress slowly, such as in the case of the cardiac
muscles, which showed relatively similar levels of functionally glyco-
sylated a-DG in all AAV-treated cohorts. However, such hypotheses
cannot be fully validated until we are able to understand the amount
of virus and the localization of viral vectors within each individual
muscle. The effort to quantify the total number of viral vector copy
numbers has been met with difficulty for interpretation, as localiza-
tion of the virus, whether in connective tissue cells or muscle fibers,
could not be determined by whole-tissue analysis. The expression
levels of the FKRP transgene are currently the only data we have,
which appear to show similar levels in the same muscle tissue of all
AAV-treated cohorts. Therefore, muscle-specific and age-related
variation in the efficiency of glycosylation of a-DG cannot be
excluded. However, it should be noted that the levels of FKRP protein
in the tibialis anterior muscles are very low and only detectable by
western blot analysis utilizing an FKRP (C-terminal) antibody.
Perhaps also relevant is that the FKRP protein is detected as a dimer,
judged by the molecular weight, as opposed to the monomer form of
FKRP, which is undetectable. It is possible that the detectable dimer
form of FKRP might not represent the actual amount or even active
form of FKRP expressed by the AAV vector.
Despite the difficulty in determining the mechanism(s) involved,
there is a clear indication that levels of functional glycosylation of
a-DG can be considerably lower in severely affected muscles and at38 Molecular Therapy: Methods & Clinical Development Vol. 5 June 2017later stages of disease progression. This has significant clinical
implications, considering the fact that most patients, even those
with relatively mild LGMD2I, are likely to have more severe muscle
degeneration and extensive extracellular matrix accumulation
compared to the muscles of a dystrophic mouse model, in which sig-
nificant fibrosis is largely limited to the diaphragm. The efficiency of
AAV viral infection, transgene expression, and/or glycosylation of
a-DG in patients is likely to be considerably lower and evenmore var-
iable than that observed in the skeletal muscles of the late-stage
treated cohorts. Our results strongly support the notion that early
treatment is critical for achieving high efficacy. Encouragingly,
AAV gene therapy at all stages of disease progression has the ability
to maintain existing muscle mass and improve, albeit limited, muscle
function as shown in our study. One possible alternative to compen-
sate for the diminishing efficiency in transgene expression and glyco-
sylation of a-DG in advanced diseases could be the use of a higher
viral dosage, which brings with it more risks that include non-target
tissue expression, loss of efficacy, and the potential to trigger anti-
capsid cytotoxic T lymphocyte responses.29 Studies related to this
issue are currently being investigated by our research group.
The effective consequence of gene replacement therapy is the expres-
sion of a therapeutic transgene product, which is the FKRP protein in
our study. Normally, this product would represent an essential
biomarker for the assessment of efficacy in a clinical trial. Detection
of the FKRP transgene by both immunohistochemistry and western
blot has been fairly straightforward using a strong promoter such as
cytomegalovirus (CMV), which we have previously reported.22 How-
ever, for clinical applications, a muscle-specific promoter such as the
CK7-based cassette is highly preferred for selective expression in tar-
geted dystrophic muscles.30 Unfortunately, the CK7-based cassette is
slightly more active but very weak compared with the CMV cassette.
At the dose of 2.5  1013 vg/kg used in this study, FKRP transgene
expression can only be detected weakly by western blot and cannot
be convincingly identified in almost all muscle fibers by immunohis-
tochemistry. In contrast, detectable levels of functional glycosylation
of a-DG are demonstrated without much difficulty. Previous immu-
nohistochemical colocalization results have shown that restoration of
functional glycosylation of a-DG can be achieved in fibers without
detectable signals for FKRP.22 This suggests that detectable levels of
FKRP protein are not necessarily required for the restoration of
normal levels of functional glycosylated a-DG and subsequent rescue
of the dystrophic phenotype. It should be noted that this does not
contradict the observed efficacy shown by the restored functional
glycosylation of a-DG and improvement in muscle function. In
fact, one major obstacle for FKRP-related muscular dystrophies has
been the inability to detect endogenous FKRP protein despite
great efforts.31 In the last decade, many antibodies against FKRP
peptide sequences have been produced, including FKRP829-STEM
(Dr. Derek J. Blake, Cardiff University), FKRP (C-16) (Santa Cruz
Biotechnology), and FKRP (C-terminal) antibody (our laboratory),
none of which have convincingly detected endogenous FKRP. This
suggests that the level of functionally glycosylated a-DG may be a
more reliable and direct biomarker for therapeutic efficacy until a
www.moleculartherapy.orgmore sensitive and consistent detection method for FKRP can be
developed.
In conclusion, this study provides direct evidence that a single-dose
therapy can result in viable FKRP expression that is able to success-
fully generate functional glycosylation of a-DG and ameliorate the
dystrophic phenotypes at multiple stages of disease progression.
Our results are particularly important with regard to the clinical
translation of FKRP gene therapy, suggesting that early therapeutic
interventions are critical for achieving high efficacy and are likely to
have the best chance to counteract the deleterious effects of LGMD2I.
Conversely, substantial correction of the disease pathology is unlikely
to occur in the advanced stages of disease progression, where muscle
tissue is progressively replaced by adipose and fibrotic tissue. Never-
theless, limited benefits are achievable for more advanced stages of the
disease.
MATERIALS AND METHODS
Study Design
Rationale and Design of Study
This was a proof-of-concept study designed to search for possible
differences among experimental treatment groups. Animals were
assigned to treatment groups on the basis of availability of gene
replacement vector.
Randomization and Blinding
This was an open-label and non-randomized study.
Replication
Repeated functional measures were conducted over time in animals as
indicated. Technical replicates were performed in immunohisto-
chemical, western blot, quantitative real-time PCR, and histological
analyses.
Ethics Statement
All animal studies were approved by the Institutional Animal Care
and Use Committee (IACUC) of Carolinas Medical Center. All
mice were housed in the vivarium of Carolinas Medical Center ac-
cording to animal care guidelines of the institute. Food and water
were available ad libitum during all phases of the study.
Mouse Model
FKRPP448L mutant mice were generated by the McColl-Lock-
wood Laboratory for Muscular Dystrophy Research.25,26 These
mice contain a homozygous missense mutation (c.1343C > T,
p.Pro448Leu) in the FKRP gene with the floxed neomycin resistant
(Neor) cassette removed from the insertion site.
Construction of AAV Vector and Administration
The recombinant AAV vector construction was performed as
described previously.32 Full-length human FKRP cDNA was synthe-
sized for high expression in mice and was subsequently subcloned
into a single-stranded AAV9 vector under control of a muscle-specific
CK7 promoter. Recombinant AAV vector stocks were produced ac-Molcording to the three-plasmid cotransfection method reported
previously.33 The viral particles were purified twice by cesium chlo-
ride density gradient ultracentrifugation using the previously
published protocol.34 Vector titers were determined by both dot-
blot and real-time PCR methods using previously published
protocols.35,36 The concentration of viral vectors was kept in the range
of 5  1012 vg/mL and stored at 80C until future use.
FKRPP448L mutant mice were administered with AAV9-FKRP at a
dose of 2.5 1013 vg/kg via a single tail-vein injection at four different
age points: 5, 13, 26, and 39 weeks (n = 4 for each cohort; 2 male and
2 female). Mice were euthanized 13 weeks after injection. All un-
treated FKRPP448L mutant mice (n = 4 for each cohort; 2 male and
2 female) were euthanized at the same age point as the AAV-treated
mice. FKRPP448L mutant mice (n = 4 for each cohort; 2 male and
2 female) aged 5 and 13 weeks were used as controls for fibrotic
area comparisons. C57BL/6 mice (n = 2; 1 male and 1 female) aged
14 weeks were used as controls for western blot normalization.
Immunohistochemical and Western Blot Analysis
Tissues were dissected and snap-frozen in dry-ice-chilled 2-methyl-
butane. Tissues were cryosectioned (6-mm thick), positioned on glass
microscope slides, and then stored at 80C until future use. Anti-
bodies used in this study were obtained as follows: mouse monoclonal
a-DG (clone IIH6C4) was from EMD Millipore, rabbit polyclonal
actin and laminin was from Sigma-Aldrich, rabbit polyclonal glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH) was from Thermo
Fisher Scientific, and an affinity-purified rabbit polyclonal FKRP
(C-terminal, sequence: NPEYPNPALLSLTGG) was produced in
our laboratory.
For immunohistochemical detection, frozen tissue sections were
incubated with 1 Tris-buffered saline (TBS) for 5 min and then
immediately blocked with 10% normal donkey serum diluted in
1 TBS for 30 min. Sections were then incubated overnight at
4C with primary antibodies IIH6C4 (1:200) or laminin (1:200)
diluted in 1 TBS. Sections were washed two times with 1 TBS
and appropriate secondary antibodies were incubated at room tem-
perature for 1 hr. Sections were washed three times with 1 TBS
and mounted with fluorescence mounting medium (Dako) con-
taining 1 DAPI. Images were visualized using an Olympus
BX51/BX52 fluorescence microscope (Opelco) and were captured
using the Olympus DP70 digital camera system (Opelco).
For western blot analysis, tissues were rapidly homogenized in extrac-
tion buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% SDS, and
1% Triton X-100) supplemented with 1 protease inhibitor cocktail
(Sigma-Aldrich). Non-dissolved protein was removed by centrifuga-
tion (22,000  g for 15 min at 4C). Protein concentrations were
measured using a NanoDrop 2000 spectrophotometer (Thermo
Fisher Scientific). For each lane, approximately 30 mg protein was
loaded, separated on a 4%–20% Tris-glycine polyacrylamide gel
(Life Technologies), and immunoblotted. Nitrocellulose membranes
were blocked with Protein-Free T20 (TBS) blocking buffer (Thermoecular Therapy: Methods & Clinical Development Vol. 5 June 2017 39
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1 hr at room temperature and then incubated with the following pri-
mary antibodies overnight at 4C: IIH6C4 (1:1,000), FKRP (C-termi-
nal) (1:400), actin (1:8,000), and GAPDH (1:2,000). Appropriate
horseradish peroxidase (HRP)-conjugated secondary antibodies
were applied to the membranes for 1 hr. All blots were developed
by electrochemiluminescence immunodetection (PerkinElmer),
exposed to BioMax Light Film (Sigma-Aldrich), and processed by a
Mini-Medical imaging system (AFP Imaging) or by manual film pro-
cessing. The detection of actin and GAPDH confirmed that a similar
amount of protein was loaded for each sample.
Quantitative Reverse Transcriptase PCR Assays
Total RNA was extracted from tibialis anterior tissues using TRIzol
reagent (Life Technologies), and cDNA was synthesized using a
High-Capacity RNA-to-cDNA kit (Applied Biosystems). PCR anal-
ysis was performed using PowerUp SYBR Green Master Mix (Life
Technologies), and amplified PCR products were quantified and
normalized using GAPDH as a control. Cycling conditions for
FKRP transgene expression were as follows: initial uracil-DNA glyco-
sylase (UDG) activation (50C/2 min), Dual-Lock DNA polymerase
(95C/2 min), 40 cycles (95C/15 s; 55C/15 s; and 72C/1 min).
This was followed by melting curve analysis starting at 65C and
increasing to 95C at a programmed rate of 0.1C/s. The primer
pair used is 50-CCACAGCACAGACAGACACT-30 (forward) and
50-CTCCGGGGCATCCTTAGAAA-30 (reverse) (Integrated DNA
Technologies). All reactions were performed in triplicate.
Histopathological and Morphometric Analysis
Frozen tissue sections were processed for H&E staining using stan-
dard procedures. For H&E images, one representative 40 magnifi-
cation image from each cohort was used. For morphometric analysis,
tibialis anterior muscles were subject to immunostaining as described
above with rabbit anti-laminin primary antibody (Sigma-Aldrich)
and an anti-rabbit IgG (H+L) secondary antibody, Alexa Fluor 594
conjugate (Life Technologies). Muscle cross-sectional fiber radii
and the percentage of myofibers with centrally located nuclei were
quantified manually from photographs taken at 10 magnification
(average ofR450 fibers). Images were visualized using an Olympus
BX51/BX52 fluorescence microscope and were captured using the
Olympus DP70 digital camera system. All measurements and calcu-
lations were conducted using MetaMorph Microscopy Automation
and Image Analysis Software (version 7.7.0.0; Molecular Devices).
Masson’s Trichrome Staining
Tissue slides were thawed and fixed in 10% neutral buffered formalin
overnight at room temperature, rinsed with water, and then baked at
56C in Bouin’s fixative for 1 hr. Slides were rinsed with water and
then dipped in Weigert’s iron hematoxylin for 10 min. Slides were
washed twice in deionized water and then incubated in Biebrich
scarlet-acid fuchsin solution for 30 min. After a brief washing in de-
ionized water, slides were put in phosphotungstic phosphomolybdic
acid for 12 min and stained with aniline blue for 20 min. Slides
were washed in deionized water and subsequently placed in acidified40 Molecular Therapy: Methods & Clinical Development Vol. 5 June 2017ethanol containing 1% glacial acetic acid for 2 min. Slides were then
dipped three times each in 95% ethanol, 100% ethanol, and xylene
(Sigma-Aldrich). All reagents were acquired from Poly Scientific
R&D unless otherwise stated. Masson’s trichrome was used to deter-
mine the amount of fibrosis within the diaphragm, which was calcu-
lated from the entire muscle cross-sectional area and quantified using
ImageJ software (Java version 1.6.0_20; NIH). The color threshold of
the images was adjusted in ImageJ using the hue/saturation/bright-
ness filter sets dividing the image into two-color ranges. Particles
on the created masks were subsequently analyzed and the total areas
were used to create the blue-to-total ratio indicating the percentage of
fibrous tissue. One representative 20 magnification image for each
diaphragm per animal was used.
Treadmill Exhaustion Test
All mice were subjected to a treadmill exhaustion test. Mice were
placed on the belt of a five-lane motorized treadmill (Columbus In-
struments) supplied with shock grids mounted at the back of the
treadmill, which delivered a 0.2-mA current to provide motivation
for exercise. Initially, the mice were subjected to an acclimation
period (time, 5 min; speed, 8 cm/s; distance, 24 m; and incline,
0). Immediately after the acclimation period, the test commenced
at a speed of 8 cm/s and was subsequently increased 2 cm/s every min-
ute until exhaustion. The test was stopped and the time to exhaustion
was determined when the mouse remained on the shock grid at the
back of the treadmill for 5 s without attempting to re-engage the
treadmill or if the mouse repeatedly failed to make it at least halfway
up the treadmill lane. Stop times were rounded to the nearest 15-s
interval.
Whole-Body Plethysmography
Respiratory functional analysis in conscious, freely moving mice was
measured using a whole-body plethysmography technique. The
plethysmograph apparatus (emka Technologies) was connected to a
ventilation pump for the purpose of maintaining constant air flow,
a differential pressure transducer, a USBamp signal amplifier, and a
personal computer running iox2 software (emka Technologies)
with the respiratory flow analyzer module, which was used to detect
pressure changes due to breathing and recording the transducer
signal. 20 mL of air was injected and withdrawn via a 20-mL syringe
into the chamber for the purpose of calibration. Mice were placed in-
side the plethysmograph chamber and allowed to acclimate for 5 min
in order to minimize any effects of stress-related changes in ventila-
tion. Resting ventilation was measured for a duration of 15 min after
the acclimation period. Body temperatures of all mice were assumed
to be 37C and to remain constant during the ventilation protocol.
Transthoracic Echocardiography
Transthoracic echocardiography was performed on anesthetized
(1%–2% isoflurane) mice using the SonixTablet Ultrasound System
(BK Ultrasound). Mice were held in a supine position on a mouse
monitor pad, the anterior chest wall was shaved, warm ultrasound
gel was applied to the chest area, and the transducer probe was placed
over the left hemithorax. Multiple short axis M-mode images of the
www.moleculartherapy.orgleft ventricle were obtained and these images were analyzed for left
ventricular function parameters in triplicate. The heart was also
imaged under B-mode with the B-mode placement imaging the heart
at the level of the aortic sphincter. Cardiac examination time was
approximately 15 min.
Statistical Analysis
All data are expressed as means ± SEM unless stated otherwise. Sta-
tistical analyses were performed with GraphPad Prism software
(version 7.01 for Windows; GraphPad Software). Individual means
were compared using multiple Student’s t tests. Differences were
considered to be statistically significant at p % 0.05, p % 0.01, or
p% 0.001.
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